

## CIBM Annual Symposium 2022

Campus Biotech, Geneva | 30th November


## Towards Multiple Sclerosis Assessment through Advanced MRI Biomarkers and Artificial Intelligence

Pedro M. Gordaliza<sup>a,b,c</sup>, Joe Najm<sup>b,d</sup>, Maxence Wynen<sup>b,e,f</sup>, Nataliia Molchanova<sup>b,c,g</sup>, Francesco La Rosa<sup>d,h</sup>, Jean-Philippe Thiran<sup>a,b,d</sup>, Pietro Maggi<sup>f,i,j</sup>, Benoit Macq<sup>e</sup>, Cristina Granziera<sup>k,l</sup>, Martina Absinta<sup>m,n</sup>, Meritxell Bach Cuadra<sup>a,b,c</sup>


<sup>a</sup> CIBM Center for Biomedical Imaging, Switzerland, <sup>b</sup> Radiology Department, Lausanne University and University Hospital, Switzerland <sup>c</sup> University of Lausanne, Switzerland, <sup>d</sup> Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland, <sup>e</sup> ICTeam, UCLouvain, Louvain-la-Neuve, Belgium, <sup>f</sup> Louvain Inflammation Imaging Lab (NIL), Institute of Neuroscience (IoNS), UCLouvain, Brussels, Belgium, <sup>9</sup> University of Applied Sciences of Western Switzerland, Switzerland, <sup>h</sup> Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, <sup>i</sup>Department of Neurology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium, <sup>j</sup>Department of Neurology, CHUV, Lausanne, <sup>k</sup> Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, University Hospital Basel and University of Basel, Switzerland, <sup>1</sup> Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel,

m IRCCS San Raffaele Hospital and San Raffaele University, Italy, n Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

## **BACKGROUND**



- Approximately 2.3 million people worldwide live with Multiple Sclerosis (MS)<sup>1</sup>.
- Autoimmune inflammatory disease of the central nervous system affecting myelin sheath damaging it and the nerves, degrading or interrupting the information flow.
- Degenerative disease, increased patient disability through time, without curation.
- MS lesion assessment in-vivo with MRI.
- During clinical practice, monitoring White Matter Lesions (WML).
- Advanced MRI sequences allow the discovery of more informative biomarkers for research: Cortical Lesions (CL), Parametric Rims (PRL) and Central Veins Sings (CVS)<sup>2</sup>.



[1] Filippi et al. Nat. Rev. Dis. Primers. 2018, [2] La Rosa et al. Neurolmage Clin. 2022

## AIMS



- Automated segmentation and/or detection of advanced biomarkers aligned with the MSxplain project goals:
  - Improve the automation model's generalization capabilities by identifying existence bias.
  - o Increase confidence in the clinical decision-making process through new interpretability and explainability strategies.
  - Extract measures of MS progression modelling the possible cause and effects relations underlying the disease's biological mechanisms

